lidocaine and Tenosynovitis

lidocaine has been researched along with Tenosynovitis in 19 studies

Lidocaine: A local anesthetic and cardiac depressant used as an antiarrhythmia agent. Its actions are more intense and its effects more prolonged than those of PROCAINE but its duration of action is shorter than that of BUPIVACAINE or PRILOCAINE.
lidocaine : The monocarboxylic acid amide resulting from the formal condensation of N,N-diethylglycine with 2,6-dimethylaniline.

Tenosynovitis: Inflammation of the synovial lining of a tendon sheath. Causes include trauma, tendon stress, bacterial disease (gonorrhea, tuberculosis), rheumatic disease, and gout. Common sites are the hand, wrist, shoulder capsule, hip capsule, hamstring muscles, and Achilles tendon. The tendon sheaths become inflamed and painful, and accumulate fluid. Joint mobility is usually reduced.

Research

Studies (19)

Authors

Clinical Trials (5)

Trial Overview

Trial Outcomes

Adverse Outcomes (Hemorrhage, Infection, Hematoma, Extravasation)

(NCT00651625)
Timeframe: during procedure, 2 weeks afterwards, and 6 months afterwards

Aspirated Fluid Volume

Aspirated fluid volume during procedure (NCT00651625)
Timeframe: during procedure

Pain Using VAS (Visual Analogue Pain Scale)

0-10 cm VAS pain scale at 2 weeks compared to 0-10 cm VAS pain scale at 0 weeks where 0= no pain, and 10 = the worst pain imaginable. The difference (2 week VAS-0 week VAS) is the primary outcome measure. (NCT00651625)
Timeframe: 2 weeks

Physician Satisfaction

"0- 10 cm visual analogue satisfaction scale (VASS)~0-10 cm VASS at 2 weeks compared to 0-10 cm VASS pain scale at 0 weeks where 0= completely dissatisfied, and 10 = completely satsified. The difference (2 week VAS-0 week VAS) is the outcome measure" (NCT00651625)
Timeframe: during procedure

Number of Participants With no Symptoms of Trigger Finger

"Number of participants with no symptoms of trigger finger 1 year after the initial encounter for both groups. Outcomes were determined clinically:~The Quinnell grading system was used for objectively evaluating the trigger finger. This grading system is a scale of 0-4 for severity of triggering with 0 being no triggering." (NCT03641508)
Timeframe: 1 year

Number of Participants With no Symptoms of Trigger Finger

"Number of participants with no symptoms of trigger finger 6 months after the initial encounter for both groups. Outcomes were determined clinically:~The Quinnell grading system was used for objectively evaluating the trigger finger. This grading system is a scale of 0-4 for severity of triggering with 0 being no triggering." (NCT03641508)
Timeframe: 6 months

Number of Participants With no Symptoms of Trigger Finger

"Number of participants with no symptoms of trigger finger 6 weeks after the initial encounter for both groups. Outcomes were determined clinically:~The Quinnell grading system was used for objectively evaluating the trigger finger. This grading system is a scale of 0-4 for severity of triggering with 0 being no triggering." (NCT03641508)
Timeframe: 6 weeks

Difference in Visual-analog Score (VAS) for Anticipated Pain Prior to Injection and Actual Pain After Injection

Members of both study groups completed the Visual Analog Scale (VAS) pain assessment both prior for anticipated pain and after injection for actual pain; these recorded scores were the primary study endpoint and were later compared to determine the difference in anticipated pain versus actual pain experienced. The VAS ranges from 0-10, where 0 is no pain and 10 is worst possible pain. The outcome measure is the mean anticipated pain minus the actual pain experienced. (NCT02084706)
Timeframe: Our outcome measure was collected within the 60 seconds before and following the steroid injection.

Degree of Triggering

A Green classification number (0-4) is given to each subject pre-injection and at 6 weeks post-injection based on their degree of triggering. 0 = No triggering, no pain; 1 = Pre-triggering; pain, history of catching, but not demonstrable on physical examination; tenderness over the A1 pulley; 2 = Active; demonstrable catching, but the patient can actively extend the digit; 3= Passive; demonstrable catching requiring passive extension or inability to actively flex; and 4 = Contracture; demonstrable catching with a fixed flexion contracture of the PIP joint. (NCT02421419)
Timeframe: Patients are assessed pre-injection objectively by investigator and at 6 weeks post-injection subjectively via Patient Survey

Number of Participants With Adverse Effects

Incidence of adverse effects (NCT02421419)
Timeframe: Patients are assessed 1 minute post-injection, 10 minutes post-injection, and at 6 week post-injection.

Presence of Triggering

Patients are asked how often their finger triggers - not at all, rarely, occasionally, or frequently at time intervals indicated in the outcome measure time frame. Count of participants for each of these answers was collected. (NCT02421419)
Timeframe: Patients are assessed pre-injection (baseline), 1 minute post-injection, 10 minutes post-injection, and 6 weeks post-injection

VAS

Visual Analogue Pain Scale (VAS) - measurement of pain on scale of 0 (least) to 10 (worst). (NCT02421419)
Timeframe: Patients are assessed pre-injection (baseline), 1 minute post-injection, 10 minutes post-injection, at 6 weeks post-injection and also asked to recollect their pain at time of injection when seen at 6 weeks post-injection

Reviews

1 review available for lidocaine and Tenosynovitis

Trials

3 trials available for lidocaine and Tenosynovitis

Other Studies

15 other studies available for lidocaine and Tenosynovitis